The FDA's Endocrinologic and Metabolic Drugs Advisory Committee meets Thursday to review Saxenda (liraglutide) to treat obesity. If the drug passes muster, it could give Novo Nordisk A/S a new entry into the market for weight loss therapies and extend use of the drug, which is already sold at a lower dose as Victoza for type 2 diabetes.